...

Instem and Sable Bio Partner to Speed Up Target Risk Assessment With AI-Powered Scientific Intelligence

Sable Bio

Instem announces strategic partnership with Sable Bio. The two companies seek to transform target risk assessment for biopharmaceutical organizations. Instem is a leading provider of software solutions and scientific services to the drug discovery and development industry. Together, the partners will change the way teams assess safety and risk for targets. 

KnowledgeScan™ is a new platform that brings together the Target Intelligence technology owned by Sable Bio and the science-based expertise of Instem. The collaboration allows for faster and much wider target assessment. Their integration indeed results in enhancement of the KnowledgeScan technology developed earlier by Instem.

KnowledgeScan is available now. Instem has introduced it as SaaS software that is cloud-based. Researchers can use the software to access information quickly. They can also produce target intelligence reports on their own. They can also contact Instem’s team of scientific experts whenever necessary. This team will provide additional analysis, and help with explanations and solutions.

This platform is a combination of Artificial Intelligence (AI) fueled literary intelligence with professional evaluation practices. As a result, organizations are able to pinpoint possible danger obligations sooner, while they also conduct a wider analysis of scientific data. The teams, therefore, become more educated in making decisions regarding development.

Vik Krishnan, CEO at Instem, explained the thinking behind the integration.

“By integrating Sable Bio’s innovative Target Intelligence technology into KnowledgeScan, we’re creating a powerful new approach to target evaluation. Our clients benefit from immediate access to high-value scientific insights while retaining the expert interpretation and contextual understanding that remain essential for effective decision-making in drug development,” said Vik Krishnan, CEO at Instem.

Leaders Share Their Vision and the Key Benefits

Josh Almond-Thynne, CEO at Sable Bio, shared a similar view.

“Together, Sable Bio and Instem are combining advanced intelligence capabilities with deep domain expertise to help researchers evaluate potential risks faster, reduce manual effort, and focus resources on the most promising development opportunities,” said Josh Almond-Thynne, CEO at Sable Bio.

KnowledgeScan offers several clear advantages for research teams. First, users gain immediate access to comprehensive target intelligence. Second, automation and broader evidence discovery increase scientific productivity. Third, experienced safety scientists provide expert interpretation. Finally, teams enjoy faster target evaluation and improved confidence in development strategy.Overall, the partnership gives biopharmaceutical organizations a practical path to earlier, better-informed safety decisions. Instem and Sable Bio combine automation with human expertise. Thus, researchers can focus resources on the most promising opportunities.

Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.

News Source: Businesswire.com